康华生物涨2.03%，成交额1.60亿元，主力资金净流出1036.66万元

Group 1 - The core viewpoint of the news is that Kanghua Biological has experienced fluctuations in stock price and financial performance, with a notable decrease in revenue and net profit year-on-year [1][2][3] Group 2 - As of January 9, Kanghua Biological's stock price increased by 2.03% to 75.50 CNY per share, with a total market capitalization of 9.811 billion CNY [1] - The company has seen a year-to-date stock price increase of 4.48%, but a decline of 4.50% over the past 20 days and 2.84% over the past 60 days [1] - Kanghua Biological's main business involves comprehensive research, development, and operation of vaccines, with 99.99% of its revenue coming from non-immunization planning vaccines [1] Group 3 - As of September 30, the number of shareholders for Kanghua Biological increased by 6.13% to 18,300, while the average number of circulating shares per person decreased by 8.10% to 6,502 shares [2] - For the period from January to September 2025, Kanghua Biological reported a revenue of 840 million CNY, a year-on-year decrease of 20.78%, and a net profit attributable to shareholders of 189 million CNY, down 53.41% year-on-year [2] Group 4 - Since its A-share listing, Kanghua Biological has distributed a total of 686 million CNY in dividends, with 462 million CNY distributed over the past three years [3] - As of September 30, 2025, the fifth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 1.1826 million shares as a new shareholder [3] - The seventh largest circulating shareholder is Southern CSI 1000 ETF, holding 850,600 shares, which is a decrease of 11,100 shares compared to the previous period [3]